The Drug Desensitization Market size was valued at US$ 602.10 Million in 2024, expanding at a CAGR of 8.07% from 2025 to 2032.
The drug desensitization market includes therapeutic interventions and structured clinical protocols aimed at temporarily increasing patient tolerance to critical medications in people with known hypersensitivity or allergic reactions, allowing them to continue receiving treatment in controlled healthcare settings. The growing prevalence of drug allergies, as well as the increasing reliance on essential first-line therapies such as antibiotics, chemotherapy agents, and biologics for the treatment of serious and life-threatening conditions, are driving market growth. A significant market trend is the shift toward personalized, protocol-based desensitization strategies that are supported by advanced diagnostic tools and patient monitoring technologies. Nonetheless, the requirement for highly trained medical personnel, intensive clinical oversight, and the associated high treatment costs serve as a major constraint. Despite these limitations, rising clinician awareness and the increasing use of biologics and oncology treatments present significant opportunities for the widespread implementation of standardized desensitization programs in hospitals and specialty care settings.
Drug Desensitization Market- Market Dynamics
Rising Prevalence of Drug Hypersensitivity Reactions
The increasing incidence of drug hypersensitivity reactions is a major factor driving global demand for drug desensitization therapies. As the pharmaceutical industry continues to expand into new therapeutic areas, a growing number of patients are experiencing immune-mediated adverse reactions to essential medications, including antibiotics, chemotherapeutic agents, and biologics. These hypersensitivity reactions vary widely in severity, ranging from mild skin rashes to severe, life-threatening allergic responses, posing significant challenges to effective and continuous treatment. According to a March 2023 review article titled "Pathogenesis of Allergic Diseases and Implications for Therapeutic Interventions," drug hypersensitivity reactions account for approximately 5-10% of all adverse drug reactions and affect nearly 7-10% of the global population. While self-reported drug allergies occur in about 8% of individuals, confirmed cases are considerably lower. In pediatric populations, suspected hypersensitivity reactions affect 1-2%, with confirmed cases around 0.05%. Antibiotics remain the most common triggers, responsible for nearly 30% of severe reactions, including Stevens-Johnson syndrome.
Drug Desensitization Market- Segmentation Analysis:
The worldwide market is segmented on the basis of Type, End-Users, Sales Channel, and Region.
In terms of types, Sublingual Immunotherapy (SLIT), with its numerous patient-centered benefits, is now the market leader in global drug desensitization, accounting for 66.1% by 2025. The most significant factor in the patient-friendly benefits is the administration of allergenic extracts or therapeutic agents under the tongue, which patients perform themselves, providing an easy and comfortable way of treatment at home while avoiding the hassle of frequent clinic visits.
In October 2023, the American Academy of Allergy, Asthma, and Immunology (AAAAI) reported that sublingual immunotherapy (SLIT) resulted in 60% desensitization and 48% remission in peanut-allergic children over three years. According to the research, early childhood intervention is a critical factor in facilitating drug desensitization and long-term allergy remission.
Hospitals and specialized allergy clinics are the largest end-users in the global drug desensitization market. This dominance stems from their ability to combine advanced diagnostic capabilities, specialized clinical expertise, and multidisciplinary patient management in controlled healthcare settings. These facilities are uniquely equipped to perform complex drug desensitization procedures by utilizing individualized dosing protocols, continuous patient monitoring, and close supervision by immunology and allergy specialists, ensuring safe, precise, and evidence-based care. The importance of hospitals and specialty clinics in this segment is emphasized by regulatory approvals of advanced desensitization therapies. For example, in February 2024, the United States Food and Drug Administration approved Xolair (omalizumab), developed by Genentech and Novartis, as the first medication shown to reduce allergic reactions to multiple foods after accidental exposure. This approval, which extends the use to adults and children aged one year and older with IgE-mediated food allergies, emphasizes the critical role of hospital-based and specialty clinics in administering and managing advanced desensitization treatments.
Drug Desensitization Market- Geographical Insights
North America represents a significant region in the global drug desensitization market in 2025, supported by its highly advanced healthcare infrastructure, strong concentration of pharmaceutical and biotechnology companies, and supportive government policies that promote innovation in allergy management and immune tolerance therapies. The region also benefits from substantial public and private investments in research and development, which continue to drive therapeutic advancements and clinical adoption. For example, in September 2025, ARS Pharmaceuticals, a U.S.-based biopharmaceutical company, received regulatory approval in Japan for Neffy, the first and only needle-free epinephrine nasal spray indicated for the emergency treatment of allergic reactions and anaphylaxis. Developed in collaboration with Alfresa Holdings, which will commercialize the product in Japan, Neffy is expected to be available in the fourth quarter of 2025 for adults and pediatric patients weighing more than 15 kilograms.
United States Drug Desensitization Market- Country Insights
The U.S. drug desensitization market remains the largest globally, supported by substantial investments in research and development, advanced healthcare infrastructure, and a high prevalence of drug and food sensitivities among patients. The strong presence of leading pharmaceutical companies such as Regeneron Pharmaceuticals and Horizon Therapeutics, along with well-established specialized allergy treatment centers, is accelerating the adoption of advanced desensitization protocols across the country. For instance, in September 2023, Nestle divested its peanut allergy treatment Palforzia to U.S.-based Stallergenes Greer, a recognized leader in allergen immunotherapy and drug desensitization. Palforzia, the first oral therapy approved by the U.S. FDA for peanut allergy, was originally acquired by Nestle in 2020 for USD 2.1 billion but experienced limited commercial uptake. This acquisition positioned Stallergenes Greer as the first company to offer therapies for both respiratory and food allergies, while enabling Nestle to refocus its strategic priorities on gastrointestinal treatments.
Drug Desensitization Market- Competitive Landscape:
The drug desensitization market is moderately consolidated, with established pharmaceutical companies, specialized allergy therapy providers, and emerging biotech firms specializing in immunology and hypersensitivity management. Market participants compete by developing new products, expanding clinical indications, and forming strategic alliances with hospitals and specialty allergy clinics. Companies are increasing their investment in research and development to improve desensitization protocols, improve patient safety, and broaden applications for food, drug, and biologic allergies. Regulatory approvals and acquisitions remain critical strategies for improving market positioning and expanding product portfolios. Leading players in the market include ALK-Abello A/S, HollisterStier Allergy (Jubilant Pharma), All Cure Pharma Pvt Ltd, and Allergopharma GmbH and Co KG. They use clinical expertise and global distribution networks to maintain a competitive edge and drive market growth.
Recent Developments:
In February 2025, ALK-AbellA/S, a Danish-based global specialty pharmaceutical company specializing in allergy immunotherapy and allergic asthma, has received FDA approval for its DACTRAtablet to treat house dust mite-induced allergic rhinitis in children aged five to eleven. This expands its previous approval for patients aged twelve to sixty-five and strengthens ALK's position in drug desensitization therapy.
In January 2025, Stallergenes Greer, a Swiss biopharmaceutical company that specializes in allergen immunotherapy, has received European Commission approval to extend Palforzia for the treatment of toddlers aged one to three who have a confirmed peanut allergy. Palforzia, the first oral drug desensitization therapy approved by the EMA and the FDA for this age group, promotes tolerance to peanut allergens and reduces the risk of severe allergic reactions.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL DRUG DESENSITIZATION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- IDEXX Laboratories Inc
- ALK-Abello A/S
- HollisterStier Allergy (Jubilant Pharma)
- All Cure Pharma Pvt Ltd
- Allergopharma GmbH and Co KG
- HAL Allergy Group
- LETI Pharma
- Torii Pharmaceutical Co Ltd
- Inmunotek S.L.
- Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
- DBV Technologies SA
- Prota Therapeutics Pty Ltd
- Stallergenes Greer
- Allergy Therapeutics pIc
- Aimmune Therapeutics Inc
- Others
GLOBAL DRUG DESENSITIZATION MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032
- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy (SLIT)
- Other emerging immunotherapy delivery methods
GLOBAL DRUG DESENSITIZATION MARKET, BY END-USERS- MARKET ANALYSIS, 2019 - 2032
- Outpatient treatment centers
- Hospitals and specialty allergy clinics
- Homecare settings
- Others
GLOBAL DRUG DESENSITIZATION MARKET, BY SALES CHANNEL- MARKET ANALYSIS, 2019 - 2032
- Online Channel
- Offline Channel
GLOBAL DRUG DESENSITIZATION MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Table of Contents
1. Drug Desensitization Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Drug Desensitization Market Snippet by Type
- 2.1.2. Drug Desensitization Market Snippet by End-Users
- 2.1.3. Drug Desensitization Market Snippet by Sales Channel
- 2.1.4. Drug Desensitization Market Snippet by Country
- 2.1.5. Drug Desensitization Market Snippet by Region
- 2.2. Competitive Insights
3. Drug Desensitization Key Market Trends
- 3.1. Drug Desensitization Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Drug Desensitization Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Drug Desensitization Market Opportunities
- 3.4. Drug Desensitization Market Future Trends
4. Drug Desensitization Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Drug Desensitization Market: Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
6. Drug Desensitization Market Landscape
- 6.1. Drug Desensitization Market Share Analysis, 2024
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Drug Desensitization Market - By Type
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
- 7.1.2. Subcutaneous Immunotherapy (SCIT)
- 7.1.3. Sublingual Immunotherapy (SLIT)
- 7.1.4. Other emerging immunotherapy delivery methods
8. Drug Desensitization Market - By End-Users
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By End-Users, 2024 & 2032 (%)
- 8.1.2. Outpatient treatment centers
- 8.1.3. Hospitals and specialty allergy clinics
- 8.1.4. Homecare settings
- 8.1.5. Others
9. Drug Desensitization Market - By Sales Channel
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Sales Channel, 2024 & 2032 (%)
- 9.1.2. Online Channel
- 9.1.3. Offline Channel
10. Drug Desensitization Market- By Geography
- 10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
- 10.2. North America
- 10.2.1. Overview
- 10.2.2. Drug Desensitization Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
- 10.2.7.1. Overview
- 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.2.7.4. U.S. Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.2.7.5. U.S. Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
- 10.2.8.1. Overview
- 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.2.8.4. Canada Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.2.8.5. Canada Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.3. Europe
- 10.3.1. Overview
- 10.3.2. Drug Desensitization Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
- 10.3.7.1. Overview
- 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.7.4. Germany Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.3.7.5. Germany Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.3.8. UK
- 10.3.8.1. Overview
- 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.8.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.8.4. UK Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.3.8.5. UK Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.3.9. France
- 10.3.9.1. Overview
- 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.9.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.9.4. France Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.3.9.5. France Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.3.10. Italy
- 10.3.10.1. Overview
- 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.10.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.10.4. Italy Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.3.10.5. Italy Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.3.11. Spain
- 10.3.11.1. Overview
- 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.11.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.11.4. Spain Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.3.11.5. Spain Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.3.12. The Netherlands
- 10.3.12.1. Overview
- 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.12.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.12.4. The Netherlands Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.3.12.5. The Netherlands Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
- 10.3.13.1. Overview
- 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.13.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.13.4. Sweden Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.3.13.5. Sweden Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.3.14. Russia
- 10.3.14.1. Overview
- 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.14.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.14.4. Russia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.3.14.5. Russia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.3.15. Poland
- 10.3.15.1. Overview
- 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.15.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.15.4. Poland Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.3.15.5. Poland Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.3.16. Rest of Europe
- 10.3.16.1. Overview
- 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.16.4. Rest of the Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.3.16.5. Rest of the Europe Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Drug Desensitization Key Manufacturers in Asia Pacific
- 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.5. APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.4.6. APAC Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.4.7. China
- 10.4.7.1. Overview
- 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.7.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.7.4. China Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.4.7.5. China Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.4.8. India
- 10.4.8.1. Overview
- 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.8.4. India Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.4.8.5. India Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
- 10.4.9.1. Overview
- 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.9.4. Japan Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.4.9.5. Japan Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
- 10.4.10.1. Overview
- 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.10.4. South Korea Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.4.10.5. South Korea Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
- 10.4.11.1. Overview
- 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.11.4. Australia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.4.11.5. Australia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.4.12. Indonesia
- 10.4.12.1. Overview
- 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.12.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.12.4. Indonesia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.4.12.5. Indonesia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.4.13. Thailand
- 10.4.13.1. Overview
- 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.13.4. Thailand Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.4.13.5. Thailand Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
- 10.4.14.1. Overview
- 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.14.4. Philippines Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.4.14.5. Philippines Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
- 10.4.15.1. Overview
- 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.15.4. Rest of APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.4.15.5. Rest of APAC Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.5. Latin America (LATAM)
- 10.5.1. Overview
- 10.5.2. Drug Desensitization Key Manufacturers in Latin America
- 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.5.5. LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.5.6. LATAM Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
- 10.5.7.1. Overview
- 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.5.7.4. Brazil Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.5.7.5. Brazil Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
- 10.5.8.1. Overview
- 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.5.8.4. Mexico Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.5.8.5. Mexico Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
- 10.5.9.1. Overview
- 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.5.9.4. Argentina Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.5.9.5. Argentina Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
- 10.5.10.1. Overview
- 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.5.10.4. Colombia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.5.10.5. Colombia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
- 10.5.11.1. Overview
- 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.5.11.4. Rest of LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.5.11.5. Rest of LATAM Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.6. Middle East and Africa (MEA)
- 10.6.1. Overview
- 10.6.2. Drug Desensitization Key Manufacturers in Middle East and Africa
- 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.6.5. MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.6.6. MEA Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
- 10.6.7.1. Overview
- 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.6.7.4. Saudi Arabia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.6.7.5. Saudi Arabia Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.6.8. UAE
- 10.6.8.1. Overview
- 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.6.8.3. UAE Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.6.8.4. UAE Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.6.8.5. UAE Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
- 10.6.9.1. Overview
- 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.6.9.4. Israel Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.6.9.5. Israel Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
- 10.6.10.1. Overview
- 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.6.10.4. Turkey Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.6.10.5. Turkey Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
- 10.6.11.1. Overview
- 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.6.11.4. Algeria Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.6.11.5. Algeria Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
- 10.6.12.1. Overview
- 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.6.12.4. Egypt Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.6.12.5. Egypt Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
- 10.6.13.1. Overview
- 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.6.13.4. Rest of MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 10.6.13.5. Rest of MEA Market Size and Forecast, By Sales Channel, 2019 - 2032 (US$ Million)
11. Key Vendor Analysis- Drug Desensitization Industry
- 11.1. Competitive Benchmarking
- 11.1.1. Competitive Dashboard
- 11.1.2. Competitive Positioning
- 11.2. Company Profiles
- 11.2.1. IDEXX Laboratories Inc
- 11.2.2. ALK-Abello A/S
- 11.2.3. HollisterStier Allergy (Jubilant Pharma)
- 11.2.4. All Cure Pharma Pvt Ltd
- 11.2.5. Allergopharma GmbH and Co KG
- 11.2.6. HAL Allergy Group
- 11.2.7. LETI Pharma
- 11.2.8. Torii Pharmaceutical Co Ltd
- 11.2.9. Inmunotek S.L.
- 11.2.10. Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
- 11.2.11. DBV Technologies SA
- 11.2.12. Prota Therapeutics Pty Ltd
- 11.2.13. Stallergenes Greer
- 11.2.14. Allergy Therapeutics pIc
- 11.2.15. Aimmune Therapeutics Inc
- 11.2.16. Others
12. 360 Degree AnalystView
13. Appendix
- 13.1. Research Methodology
- 13.2. References
- 13.3. Abbreviations
- 13.4. Disclaimer
- 13.5. Contact Us